Clinical Trial Update: Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of seribantumab plus fulvestrant in postmenopausal women with metastatic breast cancer was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Seribantumab (seribantumab)

Snippet

Sponsor: Elevation Oncology | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2020-09-02